Medtech startup SigTuple has raised Rs 33 crore (USD 4 million) in an extended Series C round led by SIDBI Venture Capital. Existing investors, including Endiya Partners and several strategic leaders from the healthcare sector, also participated in this funding round.
SigTuple Previous Funding
This funding follows a USD 4.3 million raise in March 2023, led by Accel and Endiya Partners. The new capital will be used to expand geographically, broaden the product portfolio, and support regulatory clearances. SigTuple’s Founder and CEO, Tathagato Rai Dastidar, expressed excitement about the investment from SIDBI Venture Capital, highlighting the company’s plans for global expansion and upcoming product launches in 2024.
Company Background
SigTuple, founded in 2015 by Apurv Anand, Bharath Cheluvaraju, Rohit Kumar Pandey, and Tathagato Dastidar, specializes in manufacturing intelligent robotic microscopes using artificial intelligence (AI) to automate clinical laboratory processes. The company’s core product, AI100, has been gaining significant traction in the Indian market and is now expanding into Southeast Asia, the Middle East, and North Africa, with plans to enter Europe and the Americas.
Recent Achievements
In September 2023, SigTuple’s AI100 received US FDA 510(k) approval, making it the third company globally—and the first in India—to achieve this for AI-assisted digital hematology. This milestone demonstrates SigTuple’s commitment to innovation and excellence in digital healthcare.
Investor Comments
Debraj Banerjee, Senior Fund Manager at SIDBI Venture Capital Ltd (SVCL), praised SigTuple’s ability to develop and deploy cutting-edge AI solutions. He emphasized the company’s strategic focus on partnerships and clinical integration, which positions it for rapid adoption and scaling across all areas of digital pathology.
Dr. Ramesh Byrapaneni, Managing Director of Endiya Partners and a Cardiologist turned Venture Capitalist, highlighted SigTuple’s integration of optics, robotics, microfluidics, and AI in healthcare. He noted that with the upcoming launch of its second product and a Point of Care (POC) under development, SigTuple is set to become the only company catering to all digital health needs of the Pathology Department—hematology, histopathology, and cytology.
SigTuple’s recent funding round, led by SIDBI Venture Capital, marks a significant step towards enhancing its product offerings and global presence. With strategic partnerships, regulatory clearances, and innovative AI solutions, SigTuple is well-positioned to revolutionize digital healthcare and improve patient testing worldwide.
